NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.82 -0.20 (-1.00 %) (As of 03/31/2020 11:21 AM ET) Add Compare Today's Range$18.56Now: $19.82▼$20.1950-Day Range$14.38MA: $18.70▼$27.7252-Week Range$4.26Now: $19.82▼$29.61Volume406,755 shsAverage Volume3.00 million shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/ABeta2.29 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPTI Previous Symbol CUSIPN/A CIK1503802 Webhttp://www.karyopharm.com/ Phone617-658-0600Debt Debt-to-Equity Ratio2.47 Current Ratio6.01 Quick Ratio6.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40.89 million Price / Sales31.77 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book25.09Profitability EPS (Most Recent Fiscal Year)($3.22) Net Income$-199,590,000.00 Net Margins-488.08% Return on Equity-254.74% Return on Assets-71.41%Miscellaneous Employees332 Outstanding Shares65,550,000Market Cap$1.30 billion Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive KPTI News and Ratings via Email Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:KPTI Rates by TradingView Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions How has Karyopharm Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KPTI stock has decreased by 6.7% and is now trading at $19.82. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Karyopharm Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Karyopharm Therapeutics. When is Karyopharm Therapeutics' next earnings date? Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Karyopharm Therapeutics. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc (NASDAQ:KPTI) released its quarterly earnings results on Thursday, February, 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.10. The firm earned $18.10 million during the quarter, compared to analysts' expectations of $16.48 million. Karyopharm Therapeutics had a negative return on equity of 254.74% and a negative net margin of 488.08%. View Karyopharm Therapeutics' earnings history. What price target have analysts set for KPTI? 8 analysts have issued 1 year price objectives for Karyopharm Therapeutics' shares. Their forecasts range from $25.00 to $43.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $30.71 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price. View analysts' price targets for Karyopharm Therapeutics. Has Karyopharm Therapeutics been receiving favorable news coverage? Media coverage about KPTI stock has been trending very positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Karyopharm Therapeutics earned a news impact score of 3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutKaryopharm Therapeutics. Who are some of Karyopharm Therapeutics' key competitors? Some companies that are related to Karyopharm Therapeutics include Reata Pharmaceuticals (RETA), Amarin (AMRN), Forty Seven (FTSV), United Therapeutics (UTHR), Evotec (EVTCY), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), FibroGen (FGEN), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT) and Emergent Biosolutions (EBS). What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Amarin (AMRN), Sorrento Therapeutics (SRNE), Caladrius Biosciences (CLBS) and Clovis Oncology (CLVS). Who are Karyopharm Therapeutics' key executives? Karyopharm Therapeutics' management team includes the following people: Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44) What is Karyopharm Therapeutics' stock symbol? Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI." How do I buy shares of Karyopharm Therapeutics? Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Karyopharm Therapeutics' stock price today? One share of KPTI stock can currently be purchased for approximately $19.82. How big of a company is Karyopharm Therapeutics? Karyopharm Therapeutics has a market capitalization of $1.30 billion and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe. View additional information about Karyopharm Therapeutics. What is Karyopharm Therapeutics' official website? The official website for Karyopharm Therapeutics is http://www.karyopharm.com/. How can I contact Karyopharm Therapeutics? Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected] MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 469 (Vote Outperform)Underperform Votes: 308 (Vote Underperform)Total Votes: 777MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: How is a Moving Average Calculated?
